Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Hyperdash NewsEquitiesEli Lilly and Company announced its plan to acquire Merida Biosciences for a cash consideration of up to $2.875 billion. This acquisition aims to broaden Lilly's product pipeline within a key therapeutic area. The deal signifies a major investment in the biotechnology sector.
The acquisition could bolster Lilly's long-term growth prospects by adding new assets to its development portfolio. This strategic move aligns with the pharmaceutical industry's trend of consolidation to gain access to innovative therapies and expand market share. 
First SquawkTrade these markets 24/7 on Hyperdash
Disclaimer: The content provided on Hyperdash News is for informational purposes only. We do not guarantee the quality, accuracy, or completeness of information sourced from third-party reporting. Nothing on this page constitutes financial or investment advice. Do your own research and consult a qualified financial advisor before making any investment decisions.